Dr. Lanuti is a board certified Thoracic Surgeon with special interest in lung cancer research, new techniques for lung cancer staging, and minimally invasive lung surgery.


Thoracic Surgery


Centers & Specialties

Cancer Center

Clinical Interests
  • General thoracic surgery
  • Esophageal cancer, Barrett's esophagus
  • VATS / Minimally Invasive Thoracic Surgery
  • Lung cancer and lung cancer molecular screening
  • Minimally invasive lung surgery
  • Endobroncial ultrasound for lung cancer staging
  • Navigation bronchoscopy of lung nodules
  • Radiofrequency Ablation of Lung Tumors
  • Esophageal cancer
  • Tracheobronchial disorders
  • Mediastinal tumors (Thymoma, Schwannoma, Germ Cell Tumors)
  • Palmar hyperhidrosis
  • Thymoma and surgical treatment of myasthenia gravis
Medical Education
  • MD, University of Pennsylvania School of Medicine
  • Residency, Hospital of the University of Pennsylvania
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Surgery
  • Thoracic Surgery (Cardiothoracic Vascular Surgery)
Foreign Languages
  • Spanish
  • Boston: Massachusetts General Hospital
  • Newton: Newton-Wellesley Hospital
Existing Patients
Patient Gateway
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Connecticut
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
  • Well Sense Pediatrics

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Adult and Pediatric
Provider Gender


After receiving a Bachelor of Science in BioEngineering from the University of Pennsylvania, Dr. Lanuti received his M.D. degree from the University of Pennsylvania School of Medicine (where he received the I.S. Ravdin Award for excellence in surgery). He completed his internship and residency in Surgery at the Hospital of the University of Pennsylvania and a two year research fellowship in a Thoracic Oncology Laboratory focusing on gene therapy for lung cancer. He continued with sub-specialty training, and finished a Cardiothoracic Fellowship at the Massachusetts General Hospital. He was recruited in 2004 to the staff of the Division of Thoracic Surgery, and holds a parallel appointment as Associate Professor of Surgery at Harvard Medical School. He has been the Friedman-Lambert Scholar in Academic Thoracic Surgery at MGH/HMS since 2004.  He is the Director of Thoracic Oncology for the Division of Thoracic Surgery.

Research & Publications

Research Summary

Dr. Lanuti spearheads translational research in a Thoracic Oncology Research Laboratory in conjunction with the division of Surgical Oncology and Ken Tanabe, MD. The principle goals of the laboratory are to design novel therapeutics to treat lung and esophageal cancer that can be brought to clinical trials. A primary goal is the use of oncolytic viruses to target solid tumor. Some of these strategies include development of oncolytic viruses that help degrade tumor matrix. Ultimately, this translational effort will strive to bring treatment strategies from the laboratory bench to the bedside and back to the bench again for re-evaluation and improvement.

Stage I non small cell lung cancer can still recur with a 25% chance of relapse despite complete resection.  Dr. Lanuti is investigating the role of driver mutations and gene signatures to stratify risk of recurrence in resected stage I lung adenocarcinoma. This work can contribute to adjuvant therapies for high risk resected stage I lung cancers.

The study of epidermal growth factor and its influence on biologic functions, particularly the proliferation and differentiation of epithelial tissues, has received tremendous attention. Dr. Lanuti has investigated molecular risk factors for esophageal adenocarcinoma and found an elevated risk associated with single nucleotide polymorphisms in the epidermal growth factor (EGF) gene.


View my most recent publications at PubMed

Izar B, Sequist L, Lee M, Muzikansky A, Heist RS, Iafrate AJ, Dias-Santagata D, Mathisen DJ, Lanuti M. Impact of EGFR mutation status on outcomes in patients with resected stage I NSLC. Ann Thorac Surg. 2013 Sep;96(3):962-8.

Tapias LF, Muniappan A, Wright CD, Gaissert HA, Wain JC, Morse CR, Donahue DM, Mathisen DJ, Lanuti M.  Short And Long-Term Outcomes After Esophagectomy For Cancer In Elderly Patients.  Ann Thorac Surg. 2013 May;95(5):1741-8.

Lanuti M
, Sharma A, Willers H, Digumarthy SR, Mathisen DJ, Shepard JO. Radiofrequency ablation for stage I non small cell lung cancer: management of loco-regional recurrence. Ann Thorac Surg, 2012 Mar;93(3):921-


Division of Thoracic Surgery
55 Fruit Street
Founders 7
Boston, MA 02114-2696
Phone: 617-726-6751
Fax: 617-726-7667
Newton Wellesley Hospital
2000 Washington Street
Newton, MA 02462-1650
Phone: 617-243-6447
Fax: 617-243-6449